Dermata Therapeutics Inc. (DRMA)
undefined
undefined%
At close: undefined
1.09
-0.91%
After-hours Dec 13, 2024, 05:31 PM EST

Company Description

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions.

The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.

It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions.

The company was incorporated in 2014 and is headquartered in San Diego, California.

Dermata Therapeutics Inc.
Dermata Therapeutics Inc. logo
Country United States
IPO Date Aug 13, 2021
Industry Biotechnology
Sector Healthcare
Employees 8
CEO Gerald T. Proehl

Contact Details

Address:
3525 Del Mar Heights Road
San Diego, California
United States
Website https://www.dermatarx.com

Stock Details

Ticker Symbol DRMA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001853816
CUSIP Number 249845108
ISIN Number US2498453065
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Gerald T. Proehl Founder, President, Chief Executive Officer & Chairman
Kyri K. Van Hoose CPA, M.B.A. Senior Vice President & Chief Financial Officer
David F. Hale Co-Founder & Lead Independent Director
Dr. Christopher J. Nardo M.P.H., Ph.D. Senior Vice President & Chief Development Officer
Dr. Maria Bedoya Toro Munera M.B.A., Ph.D. Senior Vice President of Regulatory Affairs & Quality Assurance
Sean Proehl Senior Director of Legal & Business Development

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 14, 2024 8-K Current Report
Nov 13, 2024 10-Q Quarterly Report
Sep 27, 2024 D Filing
Sep 24, 2024 424B3 Filing
Sep 19, 2024 S-3 Filing
Sep 17, 2024 8-K Current Report
Aug 07, 2024 S-8 Filing
Aug 07, 2024 8-K Current Report
Aug 07, 2024 10-Q Quarterly Report